China's 2026 national reimbursement drug list, released Nov. 14, admits JW Therapeutics' CAR-T therapy Carteyva to basic medical insurance via the new commercial innovative-drug list, the first CAR-T to get there. The list adds 107 drugs and takes effect Jan. 1, 2027.
Four US nonprofits sued five leading AI companies in San Francisco on Nov. 12, asking a judge to freeze development and deployment of more advanced AI models under California's Unfair Competition Law. Earlier AI lawsuits mostly sought damages over copyright or individual harm; this one asks the court to hit pause on the frontier itself.
In an interview posted on the company intranet on Nov. 12, Mercedes-Benz executives said the board has decided to stop all further investment in its German sites and will examine "concretely and in detail" which German locations it can still afford, after cost-cutting talks with the works council and the IG Metall union stalled.
On its third-quarter 2026 earnings call, Chinese chipmaker SMIC said AI computing demand is outstripping supply and that the industry expects foundry capacity to be very tight in 2027, possibly into the second half of 2028. SMIC expects full-year revenue above $12 billion, up nearly 30%. Third-quarter revenue rose 28.1% year over year to 21.98 billion yuan, while demand for phones and low-end consumer electronics stayed weak.